- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06352593
Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage
Role of Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage: A Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Aneurysmal subarachnoid hemorrhage is a sudden, life-threatening emergency caused by bleeding in the subarachnoid space between the brain and skull. Cerebral vasospasm (VSP) is the leading risk factor of neurological deterioration (i.e., delayed cerebral ischemia [DCI] and cerebral infarction) after aneurysmal subarachnoid hemorrhage (SAH) and a cause of morbidity and mortality.
Dexmedetomidine (DEX) is a highly selective α-2 adrenergic receptor agonist. The α -2 receptor agonists have a long track record of use for sedation and analgesia. It has been shown that α -2 agonists are neuroprotective in craniocerebral and subarachnoid injuries. Dexmedetomidine has a significant effect on the central nervous system and decreases the blood flow in the brain and the requirement or needs for cerebral oxygen. It also modifies memory and enhances cognitive ability effects like sedation, analgesic, and anxiolytics. Dexmedetomidine is shown to decrease catecholamine in the brain and improves the perfusion ability in the penumbra. The glutamate level is significantly reduced by Dexmedetomidine (DEX), and so injuries at the cellular level is reduced.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mohammed S Elsharkawy, MD
- Phone Number: 00201148207870
- Email: mselsharkawy@med.tanta.edu.eg
Study Locations
-
-
ElGharbia
-
Tanta, ElGharbia, Egypt, 31527
- Recruiting
- Tanta University hospitals
-
Contact:
- Mohammed S Elsharkawy, MD
- Phone Number: 00201148207870
- Email: mselsharkawy@med.tanta.edu.eg
-
Principal Investigator:
- Ahmed E Abo ElKheir, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged >18 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) I-III
- Unruptured subarachnoid hemorrhage (SAH) confirmed by digital subtraction catheter angiography (DSA) undergoing endovascular intervention with general anesthesia.
Exclusion Criteria:
- Subarachnoid hemorrhage (SAH) from a lesion other than a ruptured saccular aneurysm.
- Intraventricular or intracerebral blood in the absence of localized thick or diffuse Subarachnoid hemorrhage (SAH).
- No or localized thin subarachnoid hemorrhage (SAH) on computed tomography (CT).
- Cerebral vasospasm on admission digital subtraction catheter angiography (DSA).
- Hypotension (systolic blood pressure 90 mm Hg) refractory to fluid therapy.
- Neurogenic pulmonary edema.
- Cardiac failure requiring inotropic support.
- Severe or unstable concomitant condition or disease or chronic condition.
- Kidney and/or liver disease.
- Prior cerebral damage on computed tomography (CT) scan such as stroke (>2 cm maximum diameter).
- Pregnancy.
- Traumatic brain injury.
- Previously treated cerebral aneurysm.
- Arterial venous malformation.
- Pre-existing cerebrovascular disorder that will affect diagnosis and evaluation of Subarachnoid hemorrhage (SAH).
- Ischemic heart disease or second or third-degree atrioventricular block.
- Long-term abuse of alcohol, opioids, or sedative-hypnotic drugs.
- Obesity (body mass index [BMI] >30 kg/m2).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group D (Dexmedetomidine)
Patients will be administered Dexmedetomidine 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
|
Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
|
Placebo Comparator: Group C (placebo group)
Patients will receive normal saline (control group) .
|
Patients will receive normal saline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of vasospasm
Time Frame: 14 days after intervention
|
Vasospasm is quantified as the percent reduction in arterial diameter between baseline and digital subtraction catheter angiography (DSA).
A global assessment of vasospasm will then made and classified as none/mild (0% to 33%), moderate (34% to 66%), or severe (67% to 100%).
|
14 days after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of morbidity and mortality (M/M)
Time Frame: 6 weeks after intervention
|
Morbidity and mortality (M/M) is defined as at least one of the following: death within 6 weeks of subarachnoid hemorrhage (SAH) from any cause; new cerebral infarct within 6 weeks of subarachnoid hemorrhage(SAH) compared with post-procedure computed tomography (CT) scan; delayed ischemic neurological deficit (DIND) due to vasospasm within 14 days of subarachnoid hemorrhage (SAH); and rescue therapy.
|
6 weeks after intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Subarachnoid Hemorrhage
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 36264PR557/2/24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dexmedetomidine
-
KRL Hospital, IslamabadRecruiting
-
Ajou University School of MedicineUnknownDexmedetomidine
-
Columbia UniversityBaylor College of Medicine; University of Pittsburgh; Boston Children's Hospital and other collaboratorsCompletedSedation | DexmedetomidineUnited States
-
Aswan UniversityRecruitingDexmedetomidine | FentanylEgypt
-
Hospital Central "Dr. Ignacio Morones Prieto"RecruitingAnesthesia | DexmedetomidineMexico
-
Assiut UniversityCompletedDexmedetomidine | IntratrachealEgypt
-
Boston Children's HospitalMemorial Sloan Kettering Cancer CenterCompletedDexmedetomidine | MemoryUnited States
-
The University of Hong KongCompletedBioavailability | DexmedetomidineHong Kong
-
Cairo UniversityNot yet recruiting
-
Tri-Service General HospitalNot yet recruitingAnalgesia | Dexmedetomidine | Thoracoscopy
Clinical Trials on Intraoperative Dexmedetomidine
-
Fundació Institut de Recerca de l'Hospital de la...UnknownIntracranial Neoplasm
-
University of California, San FranciscoCarl Zeiss Meditec AGRecruitingStage IA Breast Cancer | Stage IIA Breast CancerUnited States
-
Wenzhou Medical UniversityCompletedCorneal Astigmatism | OrientationChina
-
Philipps University Marburg Medical CenterKerckhoff Heart CenterCompletedHemodynamic Instability During Anesthesia | High Risk SurgeryGermany
-
Andriy TrailinCompletedKidney Graft DysfunctionUkraine
-
Assiut UniversityNot yet recruiting
-
Sklifosovsky Institute of Emergency CareRecruitingNon-enhancing Cerebral GliomasRussian Federation
-
Parc de Salut MarRecruiting
-
Liao NingRecruitingBreast NeoplasmsChina
-
University College, LondonCompletedPituitary AdenomaUnited Kingdom